Apple has secured a significant legal victory in its ongoing battle over the blood oxygen monitoring capabilities of its flagship wearables. The International Trade Commission (ITC) has declined to revive an import ban on Apple Watches featuring a redesigned blood oxygen sensor, clearing a path for the tech giant to potentially restore a key health metric to its devices sold within the United States.
For months, consumers purchasing the latest Apple Watch models in the U.S. Have found the blood oxygen feature disabled, a direct result of a complex patent dispute with medical technology company Masimo. The recent decision by the ITC suggests that Apple’s efforts to engineer around the disputed patents have met the necessary regulatory threshold to avoid further import restrictions.
This development is more than a mere corporate win; it represents a pivotal moment for the wearable health industry. The ability to monitor blood oxygen saturation (SpO2) is a critical tool for users managing respiratory conditions or monitoring overall fitness, and the resolution of this deadlock provides a blueprint for how consumer electronics firms can navigate aggressive patent litigation through iterative design.
As a journalist with a background in computer science and software development, I have watched this case closely. The intersection of hardware engineering and intellectual property law is often where the most innovative—and most contentious—tech battles are fought. In this instance, Apple’s ability to modify its software and hardware implementation of pulse oximetry without triggering a total ban reflects a strategic pivot in its approach to Masimo’s claims.
The Core of the Conflict: Pulse Oximetry and Patents
To understand the significance of this breakthrough, one must first understand the technology at stake. Blood oxygen monitoring, or pulse oximetry, uses light-emitting diodes (LEDs) and photodiodes to measure the amount of oxygen in the blood by analyzing how light is absorbed by hemoglobin. This is a standard medical procedure that Masimo, a company specializing in non-invasive patient monitoring, has spent decades perfecting.
The dispute began when Masimo alleged that Apple had not only infringed upon its patents but had too poached key employees and proprietary secrets to develop the blood oxygen feature for the Apple Watch. The legal battle culminated in a ruling by the International Trade Commission (ITC), which found that Apple had indeed infringed on Masimo’s patents, leading to a ban on the import of Apple Watch Series 9 and Ultra 2 models equipped with the infringing technology.
In response to the ban, Apple took the unusual step of selling these watches in the U.S. With the blood oxygen feature completely disabled via software. While this allowed the company to continue selling its latest hardware, it left a glaring void in the product’s value proposition, as the SpO2 sensor remained physically present in the device but dormant.
The Redesign Strategy and ITC Ruling
The “breakthrough” in this case stems from Apple’s decision to submit a redesigned version of the blood oxygen feature to the ITC. Rather than attempting to fight the validity of Masimo’s patents in a protracted court battle alone, Apple focused on “designing around” the specific claims of the patents in question.
By altering the way the sensor processes data and the specific algorithms used to calculate oxygen saturation, Apple aimed to create a version of the feature that provides the same consumer benefit without utilizing the proprietary methods owned by Masimo. The ITC’s refusal to revive the ban indicates that the commission found Apple’s redesign sufficiently distinct from the patented technology to no longer warrant an import prohibition.
This ruling is a critical distinction in patent law. An import ban is one of the most severe penalties the ITC can impose, as it effectively cuts off a company’s supply chain. By successfully navigating the redesign process, Apple has avoided the need to completely remove the hardware from its watches, which would have required a massive overhaul of its manufacturing process.
Impact on the Consumer Experience
For the average user, this legal maneuvering translates to a potential return of functionality. While the ITC decision removes the legal barrier to importing the redesigned watches, the actual rollout of the feature to existing U.S. Customers depends on Apple’s software deployment strategy. Users who purchased “disabled” models may see the feature return via a future watchOS update, provided the hardware in their specific device is compatible with the new, non-infringing software implementation.
The stakes for Apple are high. The Apple Watch is not just a gadget but a health tool. For users tracking sleep apnea or recovering from respiratory illnesses, the blood oxygen sensor is a primary reason for choosing the device. Restoring this feature is essential for Apple to maintain its competitive edge against other health-focused wearables that have not faced similar legal hurdles.
Broader Implications for the Tech Industry
The Apple-Masimo saga serves as a cautionary tale and a strategic guide for the broader consumer electronics industry. It highlights the increasing volatility of the “health-tech” space, where traditional medical device companies are increasingly clashing with big tech firms over the democratization of medical-grade sensors.
When a company as resource-rich as Apple is forced to disable a core feature to comply with an ITC ruling, it signals that patent holders in the medical space are gaining more leverage. Though, Apple’s successful redesign also demonstrates that technical agility—the ability to rewrite code and adjust hardware logic quickly—can be an effective defense against patent litigation.
This case also underscores the role of the ITC as a powerful regulator in the global supply chain. Because the ITC focuses on imports rather than just monetary damages, its rulings can have an immediate and devastating impact on product availability, forcing companies to prioritize compliance over long-term legal victory.
Timeline of the Apple vs. Masimo Dispute
| Event | Action/Outcome | Impact |
|---|---|---|
| Initial Filing | Masimo alleges patent infringement regarding SpO2 sensors. | Initiated legal scrutiny of Apple Watch health features. |
| ITC Ruling | ITC finds Apple infringed on Masimo’s patents. | Led to a proposed import ban on specific Apple Watch models. |
| Feature Disabling | Apple disables blood oxygen feature on Series 9 and Ultra 2 in the U.S. | Products remained on sale but lacked a key health metric. |
| Redesign Submission | Apple proposes a modified version of the SpO2 feature. | Attempt to bypass infringing patents through engineering. |
| ITC Decision | ITC declines to revive the ban on the redesigned feature. | Opens the door for the feature’s return to the U.S. Market. |
What Happens Next?
While the ITC’s decision is a major win, the legal battle is not entirely over. Patent disputes of this magnitude often move through multiple layers of the judiciary, including the U.S. Court of Appeals for the Federal Circuit. Masimo may still seek to challenge the redesign or pursue monetary damages for past infringement.
The next critical checkpoint will be the official release of a software update or a new hardware revision from Apple that explicitly re-enables the blood oxygen feature for U.S. Users. Until Apple officially announces the restoration of the service, the feature remains technically unavailable on new units sold in the United States.
this case will likely influence how Apple develops future health sensors. Whether This proves non-invasive glucose monitoring or advanced blood pressure tracking, Apple will likely employ a more rigorous “patent-first” engineering approach to avoid another public and costly standoff with medical technology firms.
As we move toward a future where wearables act as primary health screening tools, the balance between protecting intellectual property and advancing public health technology will remain a central tension in the industry. For now, Apple has found a way to keep its watches on wrists and its sensors in the game.
Do you think the return of the blood oxygen feature will influence your next wearable purchase? Share your thoughts in the comments below or share this analysis with your network.